Tumor Genomic Profiling denied as duplicate or overlapping therapy by Avalon Healthcare Solutions?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Avalon Healthcare Solutions typically requires
Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.
What works in the appeal
Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.
The Avalon Healthcare Solutions angle on Tumor Genomic Profiling
## Why Avalon Healthcare Solutions Denied Tumor Genomic Profiling as "Duplicate Therapy" — and How to Appeal
A "duplicate therapy" denial for tumor genomic profiling (also called comprehensive genomic profiling or CGP) typically means Avalon determined that a prior genomic or molecular test was already performed and covers the same clinical question. This is a common but often incorrect denial: different genomic tests interrogate different portions of the genome, use different methodologies, and answer different clinical questions. A prior single-gene or small-panel test does not make a comprehensive genomic profile redundant — and the distinction matters for determining which targeted therapies a patient may be eligible for.
## Why This Denial Is Frequently Overturned
Oncology guidelines from organizations such as the National Comprehensive Cancer Network (NCCN) recognize that comprehensive genomic profiling provides clinically distinct information compared to narrow-panel or single-analyte testing. If the prior test did not assess all clinically relevant biomarkers for the patient's tumor type and stage, the new test is not duplicative — it is additive. Documenting this distinction is the core of a successful appeal.
## Federal Appeal Framework
Under ACA Section 2719, you have the right to an internal appeal and independent external review. ERISA Section 503 requires full-and-fair review for employer plans. After a final internal denial, external review must generally be requested within approximately four months. Expedited review is available when delay would seriously jeopardize your health or treatment timeline — oncology cases often qualify.
## What to Gather Before You Appeal
- Prior test report. Obtain the full report from the earlier molecular or genomic test. Note exactly which genes, variants, or biomarkers it assessed.
- Proposed test specifications. Document which additional genes, variants, or biomarker categories the new comprehensive panel would assess that the prior test did not cover.
- Treating oncologist's medical-necessity letter. The oncologist should explain: (a) what clinical question remains unanswered after the prior test, (b) how comprehensive genomic profiling addresses that gap, and (c) how the results would directly affect treatment selection. Reference the applicable NCCN guideline for the specific cancer type generically.
- Pathology and staging records. Confirm the tumor type, stage, and any prior treatment history that makes additional genomic data clinically actionable.
## Criteria-Mapping Structure
| Avalon's denial basis | Your rebuttal | Supporting document | |---|---|---| | Prior test exists | Prior test covered only [specific genes] | Prior test report | | New test covers same scope | New panel covers additional biomarkers not in prior report | Test order + oncologist letter | | Clinical question already answered | Unanswered clinical question documented | Oncologist letter |
## Timeline
Oncology decisions are time-sensitive. File the internal appeal immediately and flag that delay affects treatment planning. Request expedited processing and provide a short clinical summary of why timely testing is essential. If the internal appeal is denied, proceed to external review without delay.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →